Azanta A/S elects two new members to its Board of Directors


Hellerup, Denmark, August 28, 2014. Azanta A/S, a Danish specialty pharmaceutical company has expanded its Board of Directors by electing Mr. David N. Gill and Dr. Thomas Kiaer as new members.

Dr. Claus Møller, Chief Executive Officer of Azanta said: “We are delighted that Mr. Gill and Dr. Kiaer will be joining the Azanta board of directors. Both are excellent business leaders within their field and their expertise and insights will be very beneficial to Azanta and its shareholders.

After the elections of Mr. Gill and Dr. Kiaer, the Azanta board will have a total of 5 members.

About David N. Gill:
David N. Gill is CFO of Endochoice, Atlanta US. He started his career in Price Waterhouse and has significant international experience and has held a variety of executive roles with Medtech and information technology companies. He has been the CFO of four public companies; Novost, Interland, CTI and NxStage. David N. Gill has led the IPOs of three companies and has executed four other public offerings.

David N. Gill graduated with cum laude honors from Wake Forest University with a B.S. in Accounting and earned a MBA from Emory University. He served on the Board of Cempra Inc. where he is chairs of the Audit Committee and on the Board of visitors of the Wake Forest University Divinity School.

About Dr. Thomas Kiaer:
Thomas Kiaer is CEO and co-owner of CFR Hospitals, Hellerup Denmark, and has a long career in the Danish National Hospital Orthopaedic Department. For more than a decade, Thomas Kiaer was the principal physician and Head of the Spine Section, Orthopaedic Department. He has a long scientific career with numerous publications in national and international journals. Thomas Kiaer received his medical degree from the University of Odense and his DMSc from the University of Copenhagen.

— ooo —

About Azanta A/S
Azanta A/S is a privately owned specialty pharma company primarily operating within oncology, women´s health and addiction medicine. The vision of Azanta A/S is to become an international market leader within specialty pharma products and innovative pharmaceutical products. Azanta A/S currently markets or makes available a string of specialty pharma products, including Nimoral, a hypoxic radiosensitizer for the treatment of head and neck cancer patients undergoing primary radiotherapy and Zybrestat, a vascular disrupting agent used for anaplastic thyroid cancer. In addition, Azanta A/S has a portfolio of low risk development projects for commercialization within the near future.

For further information, please visit

Contact Azanta:
Claus Møller
Tel: + 45 – 70 25 95 45
Fax: + 45 – 70 25 95 46

For further interest in Azanta’s specialty pharma products or investigational cancer products, please contact your local representative or Azanta’s head office.

Find representative